1-866-598-7166

A Study of ALKS 4230 Alone or in Combination with Pembrolizumab in Patients with Advanced Solid Tumours

Trial ID: NCT02799095
Kidney Cancer Type: Any


Background:

ALKS 4230 is an experimental immunotherapy drug which works by targetting a molecule called IL-2. This allows the body to send more signals to the immune system, calling for greater numbers of immune cells to come and destroy any cancerous cells.

The other drug used in this study is called Pembrolizumab (Keytruda®). It is already approved for the treatment of kidney cancer when used in combination with another drug, called Axitinib (INLYTA®).


The Trial:
This study will investigate the safety and effectiveness of ALKS 4230 alone, or in combination with Pembrolizumab. As such, you may be assigned to one of two treatment groups:

  • ALKS 4230 alone
  • ALKS 4230 with Pembrolizumab

In order to maximize effectiveness and minimize side effects, difference doses of each drug may be used to determine the optimal dosage of these medications.


Basic Eligibility:

  • All subtypes eligible
  • Advanced kidney cancer that cannot be removed by surgery
  • No further drug treatments are available or recommended
Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreAlkermes Investigational Site Principal Investigator LocationEdmonton, AB Trial StatusRecruiting
Hospital / Cancer CentreAlkermes Investigational Site Principal Investigator LocationHamilton, ON Trial StatusRecruiting
Hospital / Cancer CentreAlkermes Investigational Site Principal Investigator LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreAlkermes Investigational Site Principal Investigator LocationQuebec City, QC Trial StatusRecruiting
Hospital / Cancer CentreAlkermes Investigational Site Principal Investigator LocationMontreal, QC Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!